XML 14 R4.htm IDEA: XBRL DOCUMENT v3.24.0.1
Consolidated Statements of Operations - USD ($)
shares in Thousands, $ in Thousands
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Revenue:      
Total revenue $ 147,752 $ 140,734 $ 235,309
Operating costs and expenses:      
Cost of goods sold $ 18,848 $ 20,280 $ 12,871
Cost, Product and Service [Extensible List] Product Revenue, Net [Member] Product Revenue, Net [Member] Product Revenue, Net [Member]
Research and development $ 282,861 $ 296,791 $ 387,043
Selling, general and administrative 115,252 124,688 123,925
Restructuring charge 12,606 0 0
Total operating costs and expenses 429,567 441,759 523,839
Loss from operations (281,815) (301,025) (288,530)
Interest and other, net      
Interest expense (15,532) (1,440) (1,075)
Interest income and other income (expenses), net 10,480 7,596 (1,078)
Total interest and other, net (5,052) 6,156 (2,153)
Loss before income taxes (286,867) (294,869) (290,683)
Provision for income taxes 3 358 347
Share of Net Income 2,638 1,573 1,007
Net loss $ (284,232) $ (293,654) $ (290,023)
Net loss per share - basic $ (2.92) $ (3.14) $ (3.14)
Net loss per share - diluted $ (2.92) $ (3.14) $ (3.14)
Weighted average number of common shares used to calculate net loss per share - basic and diluted      
Basic 97,303 93,582 92,349
Diluted 97,303 93,582 92,349
License Revenue [Member]      
Revenue:      
Total revenue $ 9,649 $ 22,590 $ 116,434
Development and Other Revenue [Member]      
Revenue:      
Total revenue 18,401 24,189 70,275
Product Revenue, Net [Member]      
Revenue:      
Total revenue 100,949 82,869 47,638
Drug Product Revenue, Net [Member]      
Revenue:      
Total revenue $ 18,753 $ 11,086 $ 962